NovoCure Ltd
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
NVCR$11.81-5.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations for the years ended
| Year ended December 31, | |||
|---|---|---|---|
| U.S. dollars in thousands, except share and per share data | 2023 | 2022 | 2021 |
| Net revenues | $509,338 | $537,840 | $535,031 |
| Cost of revenues | 128,280 | 114,867 | 114,877 |
| Gross profit | 381,058 | 422,973 | 420,154 |
| Operating costs and expenses: | |||
| Research, development and clinical studies | 223,062 | 206,085 | 201,303 |
| Sales and marketing | 226,809 | 173,658 | 137,057 |
| General and administrative | 164,057 | 132,753 | 126,127 |
| Total operating costs and expenses | 613,928 | 512,496 | 464,487 |
| Operating income (loss) | (232,870) | (89,523) | (44,333) |
| Financial (expenses) income, net | 41,130 | 7,677 | (7,742) |
| Income (loss) before income taxes | (191,740) | (81,846) | (52,075) |
| Income tax | 15,303 | 10,688 | 6,276 |
| Net income (loss) | $(207,043) | $(92,534) | $(58,351) |
| Basic and diluted net income (loss) per ordinary share | $(1.95) | $(0.88) | $(0.56) |
| Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share | 106,391,178 | 104,660,476 | 103,433,274 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.